KOTAK ON ALIVUS LIFE SCIENCES ; BUY | TP ₹1,630 (EARLIER ₹1,400)

• Kotak maintains Buy rating on Alivus Life Sciences and raises target price to ₹1,630 from ₹1,400. • Q2 EBITDA beats estimates, supported by better product mix, CDMO growth and one-off benefits. • EBITDA remains ahead of estimates even after excluding one-off gains. • Company raises FY27 EBITDA margin guidance to 35–36% from 30–32% earlier. • H2 margins may moderate due to a higher GNP sales mix. • Stable API pricing, new product launches and operating efficiencies expected to support margins.

ALIVUS LIFE SCIENCES LTD

← Back to feed